Biologics CDMO Market Expands with Growing Demand for mAbs, Vaccines, and Cell and Gene Therapies

The global Biologics CDMO Market is expanding rapidly due to rising demand for monoclonal antibodies (mAbs), vaccines, and advanced therapies such as cell and gene therapies, which require specialized manufacturing and development capabilities.

According to Precedence Research, the global biologics CDMO market size is expected to grow from USD 25.08 billion in 2026 to nearly USD 55.11 billion by 2035, growing at a CAGR of 9.14% from 2026 to 2035, driven by increasing biopharma outsourcing, technological advancements, and strong global investments in biomanufacturing infrastructure.

Where Data Meets Strategic Clarity 📥 View Sample Pages of the Complete Report 👉 https://www.precedenceresearch.com/sample/4943

What is a Biologics CDMO?

The global biologics CDMO market is witnessing rapid growth, primarily driven by increased demand for biologics and biosimilars. The use of biologic drugs like vaccines, recombinant proteins, and monoclonal antibodies has increased for the treatment of chronic and rare diseases. This demand shift is encouraging pharmaceutical and biotechnological companies to outsource manufacturing to CDMOs. The market growth is expected to boost in the upcoming period, with key factors, including technological advancements in biomanufacturing and growing outsourcing by biopharma companies.

The CDMO (contract development and manufacturing organization) market has witnessed an unbelievable milestone in the recent period, with significant innovative and initiative approaches by global leaders. For instance, 74% of the U.S. capitals are complying with key trends, such as biologics' capacity expansion, cell & gene therapies, ADCs, and industry consolidation. More than $24 billion was invested in the CDMO industry, majorly though reshoring efforts to U.S. companies.

🔗 What's Fueling the Next Wave of Growth? 👉 https://www.precedenceresearch.com/biologics-cdmo-market

Major Government Initiatives for Biologics CDMO:

🔹 National Biopharma Mission (India) - A government program that supports biologics innovation, biomanufacturing infrastructure, and industry-academia collaboration to accelerate the development and manufacturing of biopharmaceuticals.

🔹 National Biotechnology Strategy (Canada) - A national strategy focused on strengthening Canada's biotechnology and biomanufacturing ecosystem through funding, research support, and partnerships with CDMOs and pharmaceutical companies.

🔹 Operation Warp Speed (United States) - A government initiative launched to accelerate vaccine and biologics development and manufacturing capacity through partnerships with pharmaceutical companies and CDMOs.

🔹 Horizon Europe (European Union) - The EU's research and innovation program that funds biotechnology research, advanced therapeutics, and biomanufacturing technologies supporting biologics CDMO growth.

➡️ Become a valued research partner with us https://www.precedenceresearch.com/schedule-meeting

What are the Key Trends of the Biologics CDMO Market?

🔹 Complexity and Increased Expenses of Biologics Manufacturing: The cost of biologics manufacturing is quite high, due to their primary requirements of skilled expertise and the need to comply with strict regulatory requirements. Additionally, the growing focus on infrastructure modernization is contributing to this complexity and high cost, driven significant need for the pharmaceutical business to partner with CDMOs.

🔹 Government Initiatives for Biomanufacturing: Governments worldwide established comprehensive initiatives to support biomanufacturing industry facilities. This support includes funding, infrastructure investments, and regulatory support, enabling biomanufacturing companies to provide domestic biologics production and supply chain strengths.

Biologics CDMO Market Opportunity

High-Growth Therapeutic Modalities

The global biologics CDMO industry is likely to hold significant potential growth as biotech and pharmaceutical companies are rapidly depending on specialized partners for manufacturing and development of complex biologics products. High-growth therapeutic modalities, such as antibody-drug conjugates (ADCs) & bispecific, mRNA and peptide-based therapies, and cell and gene therapies (CGT) need highly specialized infrastructure and need to comply with strict regulatory compliance, drives need to outsource through CDMOs.

🔓 Instant Access. Zero Waiting. 📥 Buy the Premium Market Research Report Now 👉 https://www.precedenceresearch.com/checkout/4943

Biologics CDMO Market Regional Analysis:

Advanced Infrastructure: Key Pillar for the North American Biologics CDMO Industry

North America dominates the global biologics CDMO market due to its advanced infrastructure and biopharma ecosystem. North American companies are always at the forefront of investments and innovations in healthcare facilities. North America has paired high-concentration biopharma and pharmaceutical companies with substantial investments, fueling the region's R&D intensity. Additionally, as the largest home for cell and gene therapies, North America accounting dominance share in the biologics CDMO industry.

Canada Biologics CDMO Market Trends

Canada's biologics CDMO industry is experiencing strong growth driven by increasing demand for biologic drugs, biosimilars, and advanced therapies such as cell and gene therapies. Government initiatives and investments, including Canada's biomanufacturing strategy, are expanding domestic production capacity and strengthening the country's life sciences ecosystem.

Strong Government Support: Backing Up the Asian Biologics CDMO Facilities

Asia Pacific is the fastest-growing region in the global biologics CDMO industry, growth driven by its strong R&D infrastructure, rapidly expanding facilities, and strong government support. Technological advancements like increased adoption of single-use systems, AI, real-time monitoring of manufacturing, and viral vectors are also fostering this growth. The monoclonal antibodies (mAbs) segment is growing rapidly. Countries like China, South Korea, and India are witnessing growth due to government support and high-end infrastructure.

Key Government Activities to Foster the Asian Biologics CDMO Industry:

➢ Country: China
↳ Government Initiatives: Market Authorized Holder (MAH) program, Made in China, and state-backed infrastructure.

➢ Country: India
↳ Government Initiatives: Favourable FDI policies and funding for companies to diversify their supply chains.

➢ Country: South Korea
↳ Government Initiatives: National Strategic Technology Designation, Funding from Koran Drug Development, and Songdo Bio Cluster.

➢ Country: Singapore
↳ Government Initiatives: RIF program and talent developments.

India Biologics CDMO Market Trends

The Indian biologics CDMO industry is growing rapidly due to increasing demand for biosimilars, vaccines, and biopharmaceutical products. Strong government support, including initiatives to boost biomanufacturing and biotechnology innovation, is encouraging domestic production and global partnerships.

Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for decision-making.

Try Before You Buy - Get the Sample Report@ https://www.precedenceresearch.com/sample/4943

Biologics CDMO Market Segment Analysis:

Type Analysis

Which Type Segment Dominates the Biologics CDMO Market?

The mammalian type segment dominates the market because of its rapid utilization in treatment for chronic, autoimmune, and oncological diseases. The mammalian cell culture, like CHO cells, enables high efficacy for the treatments. Mammalian types can produce high-quality and complex therapeutic proteins like mAbs. Key CDMOs are highly dependent on large-scale mammalian bioreactors for handling late-phase and commercial-stage manufacturing processes.

The microbial segment is expected to grow fastest over the forecast period, driven by its ability to provide extreme and affordable vaccines, enzymes, and recombinant protein productions. This type enables rapid production through efficient fermentation. To enable large-scale production, CDMOs use cutting-edge techniques like strain engineering for systems like XS technologies.

Molecule Type Analysis

How Monoclonal Antibodies Segment Leads the Biologics CDMO Market?

The monoclonal antibodies segment leads the market, due to their increased use in clinical trials. The monoclonal antibodies have high efficiency for treating chronic diseases like cancer and autoimmune diseases. These molecules are witnessing high pipelines and increased therapeutic demands. CDMOs leverage advanced technologies like single-use systems and optimizes enabling high production efficiency of monoclonal antibody drugs.

The vaccines segment is the fastest-growing segment in the market, growth driven by increased adoption of cutting-edge technologies such as single-use bioreactors, viral vectors, and mRNA. The CDMOs enhance the vaccines' capacity and specialization by using high-containment BSL-2/BSL-3 facilities for viral vector.

Product Type Analysis

Which Product Type Segment Dominates the Biologics CDMO Market?

The biologics segment is the dominating segment in the market, primarily due to increased complex manufacturing requirements and rising regulatory approvals for biologics trials and treatments. Major pharmaceutical and biopharmaceutical companies are focusing on outsourcing to specialized CDMOs to overcome challenges like high-cost and technical risk in complex biologics manufacturing. CDMOs' outsourcing is mainly for cell and gene therapy manufacturing.

The biosimilar segment is the significant one, fostering growth due to increased need for high-volume production and the need to comply with growing demands for cost-effective alternatives. The number of patient expirations for major biologics leaded industry toward biosimilar competitors, driving significant outsourcing between biosimilar manufacturers and CDMOs.
Indication Analysis

What Made the Oncology Segment Dominating in the Biologics CDMO Market?

The oncology segment dominates the market due to the increased prevalence of cancer and the need for complex and targeted therapies like antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs). The increased cancer prevalence and treatment needs are fostering requirements of specialized and scalable manufacturing capabilities for immuno-therapies and strong investments in R&D. The demand for CDMOs has been increasing globally, due to the urgency of new and effective biologics medicine production to treat cancer patients.

The neurology segment is set to grow fastest over the forecast period, due to the increased prevalence of neurodegenerative diseases like multiple sclerosis, Parkinson's, and Alzheimer's, and the need for cutting-edge therapies for treatment purposes. CDMOs offer advanced therapeutics like new antibody therapies and gene therapies to comply with specialized manufacturing capabilities.

✚ Explore More Market Intelligence from Precedence Research:

🔹 Biologics Market Size, Share and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/biologics-market

🔹 Checkpoint Inhibitor Biologics CDMO Market Size, Share and Trends 2026 to 2034 👉 https://www.precedenceresearch.com/checkpoint-inhibitor-biologics-cdmo-market

🔹 Pharmaceutical CDMO Market Size, Share, and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/pharmaceutical-cdmo-market

🔹 Bispecific Antibodies CDMO Market Size, Share and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/bispecific-antibodies-cdmo-market

🔹 Active Pharmaceutical Ingredients CDMO Size, Share and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/active-pharmaceutical-ingredients-cdmo-market

Top Companies in the Biologics CDMO Market & Their Offerings:

➢ 3P Biopharmaceuticals S.L.U. - Provides biologics CDMO services, including cell line development, process development, analytical testing, and GMP manufacturing of recombinant proteins and monoclonal antibodies.

➢ AGC Biologics - Offers end-to-end biologics development and manufacturing services, from cell line development to clinical and commercial production of therapeutic proteins and antibodies.

➢ Binex Co. Ltd. - Specializes in microbial and mammalian cell culture-based biologics development, process optimization, and GMP manufacturing.

➢ Boehringer Ingelheim International GmbH - Provides biologics CDMO services, including cell line development, process development, and large-scale manufacturing of monoclonal antibodies and recombinant proteins.

➢ Bora Pharmaceuticals Co. Ltd. - Offers contract development and manufacturing services, including formulation development, analytical testing, and manufacturing support.

➢ Catalent Inc. - Delivers biologics CDMO services covering cell line development, drug substance manufacturing, and fill-finish solutions.

➢ Evonik Industries AG - Provides biologics development and manufacturing services, including microbial fermentation, process development, and GMP production.

➢ FUJIFILM Corp. - Offers biologics CDMO services including cell line development, process optimization, and clinical and commercial manufacturing.

➢ Rentschler Biopharma SE - Provides full-service biologics CDMO solutions, including analytical development, process development, and cGMP manufacturing.

➢ Samsung Electronics Co. Ltd. - Through Samsung Biologics, offers large-scale biologics CDMO services including cell line development, process development, and commercial manufacturing.

Recent Developments and Launch in the Biologics CDMO Industry:

🔸 On March 3, 2026, a globally leading CDMO for biologics, cutting-edge technologies, and vaccines, FUJIFILM Biotechnologies, launched its precision purification technology, ShunzymeX. This technology enables simplification of downstream processing for complex biologics. (Source: https://www.fujifilm.com)

🔸 In February 2026, FUJIFILM Diosynth Biotechnologies expanded its $546 million site in Teesside, the UK, to open the largest single-use biopharmaceutical CDMO facility in the UK. The operation capability is added for 2,000L and 5,000 bioreactors. (Source: https://healthcaretoday.com)

Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as North America, Europe, or Asia Pacific.

📥 Instant Report Delivery Available | 💳 Buy Now 👉 https://www.precedenceresearch.com/checkout/4943

Segments Covered in the Report

🔹By Type

Mammalian
Microbial

🔹By Molecule Type

Monoclonal Antibodies
Recombinant Proteins
Vaccines
Hormones
Others

🔹By Product Type

Biologics
Biosimilars

🔹By Indication

Oncology
Auto-Immune Diseases
Infectious Diseases
Neurology
Others

🔹By Geography

North America
Asia Pacific
Europe
Latin America
Middle East & Africa

Connect With Us

📞 USA: +1 804 441 9344
📞 APAC: +61 485 981 310 or +91 87933 22019 | +6531051271
📞 Europe: +44 7383 092 044
📩 Email: sales@precedenceresearch.com

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

🌐 Web: https://www.precedenceresearch.com

Our Trusted Data Partners:
🔹https://www.towardshealthcare.com
🔹https://www.towardspackaging.com
🔹https://www.towardschemandmaterials.com
🔹https://www.towardsfnb.com
🔹https://www.marketstatsinsight.com

Get Recent News:
https://www.precedenceresearch.com/news

For the Latest Update, Follow Us:
🔹https://www.linkedin.com/company/precedence-research
🔹https://x.com/Precedence_R
🔹https://www.facebook.com/precedenceresearch
🔹https://precedence-research.medium.com/

This release was published on openPR.